The research study aims to estimate the HIV incidence, retention, and assess the uptake and adherence to PrEP among at-risk Men who have sex with men (MSM) and Transgender people enrolled at the 3 partnering clinics in Kisumu, Nairobi, and Kilifi.
Objectives
- To determine the HIV incidence, retention, and the correlates of HIV acquisition among 800 MSM and Transgender people
- To assess uptake and adherence to PrEP administered as per National AIDS and STI Control Programme (NASCOP) guidelines.
- To determine the prevalence of acute HIV infection in participants reporting symptoms that are compatible with the acute retroviral syndrome at scheduled or interim visits.
Project Initiated 2019
This study commenced in October 2019 and is ongoing, despite challenges posed by the COVID-19 pandemic. PHDA is responsible for the Nairobi site and has enrolled 300 participants. The study ultimately hopes to also demonstrate that young MSM and Transgender people can be engaged and followed for 1 year at 3 counties, by 3 different research groups using standardized procedures.
Partnerships
PHDA is working with the Kenya MSM Health and Research Consortium (MHRC) and the Kenya Medical Research Institute (KEMRI) with funding from the International AIDS Vaccine Initiative (IAVI).